SecBot SecBot
6-K ·Filed Nov 13, 2026

GSK

GSK plc
NEUTRAL
Impact 4/10
Horizonmonths Processed3d 16h ago SEC0001654954-26-009743
Notable filing: 6-K
Actionable Insight • Neutral

Monitor European Commission decision expected within 2-3 months; if adopted, watch for national immunization program updates in countries with existing infant MenB programs, as adolescent booster recommendations could drive volume growth for Bexsero.

DirectionNeutral
Confidencehigh
Horizonmonths

Drug in focus

GSK drug pipeline →

Bexsero

● Neutral Named in this 6-K
Impact
Phase
Approved
Time to market
Already approved and marketed (US since 2015, EU since 2013). The booster label expansion for ages 10+ is under EMA review with a positive CHMP opinion; European Commission decision expected within 1-2 months.
Next catalyst
None dated

What to watchThe CHMP recommended Bexsero's label expansion for a single booster dose on November 13, 2026. The European Commission typically follows CHMP recommendations within 1-2 months, which would be the next catalyst. If approved, this expands the addressable adolescent/young adult booster market in Europe. Separately, Bexsero is being studied for cross-protection against gonorrhea, a potential long-term value driver, but no pivotal readout is scheduled.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$50.45
T+0 close · Nov 13, 2026 · via day close
Latest settled
−0.08%
T+1 · $50.41
Vs SPY
+1.83%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $50.45entry
  2. T+1 · 17h ago −0.08%α +1.83% · $50.41
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK announced that the EMA's CHMP has issued a positive opinion recommending a label update for Bexsero (4CMenB) to include a single booster dose for individuals aged 10+ previously vaccinated at least two years earlier. The recommendation is based on Phase IIIb data showing immune memory established in infancy can be boosted up to 19 years later. This is a regulatory milestone that could expand Bexsero's addressable adolescent booster market in Europe if adopted by the European Commission.

Key Facts

  • CHMP recommended updating Bexsero label to include a single booster dose for individuals aged 10 years and older previously vaccinated at least two years earlier
  • Recommendation based on Phase IIIb study Men-B-096 (312 participants) which met its primary endpoint
  • Bexsero is registered in 61 countries, included in 15 national/regional infant immunization programs and 3 adolescent programs in Europe
  • Around 140 million doses of Bexsero distributed globally since 2015
  • Serogroup B is the leading cause of invasive meningococcal disease in all age groups under 65 in Europe

Financial Impact

No financial figures stated in the filing; Bexsero is an established vaccine with existing market penetration; label expansion could incrementally boost sales but magnitude is not quantified

revenue

Risk Factors

  • CHMP opinion is non-binding; European Commission may not adopt the recommendation
  • Adoption by national immunization programs is not guaranteed and may take time
  • No financial impact or revenue guidance provided in the filing

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-009743
Document: 0001654954-26-009743-index-headers.html0001654954-26-009743
Document: 0001654954-26-009743-index.html0001654954-26-009743
Document: 0001654954-26-009743.txt0001654954-26-009743
Earnings Context (Synthetic; results releases only)0001654954-26-009743

Track record

64 reports on GSK

Performance horizon

9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.

Filters
  1. Nov 13, 20263d ago 6-K Neutral 4/10 Viewing Entry $50.45 Now $50.41 −0.08% settles Dec 14
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
  3. Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
  4. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
  5. Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
  7. Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
  8. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
  9. Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
  10. Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
Showing 10 of 64

US Market Status

Market Closed · Opens in 9h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026